Clinical Trial Update: Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the PET tracer ZK 6032924 in patients with Multiple Sclerosis compared to healthy volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ZK 6032924

Snippet

Sponsor: Bayer | Conditions: Positron-Emission Tomography, Multiple Sclerosis | Phase 1 | Status: COMPLETED